Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04349202 · ClinicalTrials.gov registry record

Beaumont Health Large-scale Automated Serologic Testing for COVID-19

A clinical trial, sponsored by Corewell Health East.

Completed
Registry status
20,614
Enrollment target

NCT04349202 is a clinical trial that has completed, run by Corewell Health East. The registered enrollment target is 20,614 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04349202 has completed, sponsored by Corewell Health East.

COMPLETED
Registry status
20,614 participants
Enrollment target

Study Summary

The purpose of this study is to determine how peoples' bodies respond to exposure to COVID-19. Employees of Beaumont Health in Michigan who are older than 18 years may be eligible to participate. Participants from other high-risk groups who are not Beaumont employees may also be recruited, as may family members of Beaumont employees who have tested positive for COVID-19. Participants will have blood drawn two or more times for serology testing. This serology test will determine if participants have detectable levels of the antibodies that our bodies develop to fight COVID-19 infection. Participants will fill out a questionnaire each time they provide a blood sample. The questionnaires include questions about participants' personal traits; their health; general questions about their risk to exposure; job and risk of exposure; symptoms, diagnosis, treatment of COVID-19 since last blood draw. Researchers will monitor participants' medical records in a confidential manner for one year after the last blood draw to help determine if people who develop antibodies to COVID-19 are protected against developing a COVID-19 infection in the future.There may be no direct benefits for participants; however, information from this study may benefit other people by increasing our understanding of COVID-19, how it spreads from person to person, and how people respond to fight off the infection.The results of the serology test are used for research only and will not affect clinical decisions regarding participants' treatment or quarantine

Interventions

  • DIAGNOSTIC_TEST EUROIMMUN assay

Trial Details

FieldValue
Enrollment Target 20,614 participants
Start Date 2020-04-10
Est. Completion 2021-01-19

Sponsor

Corewell Health East

106 total trials

What the Registry Record Tells You About NCT04349202

The ClinicalTrials.gov registry entry for NCT04349202 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20,614 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which EUROIMMUN assay is the first listed.

NCT04349202 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04349202 about?

NCT04349202 is a clinical study titled "Beaumont Health Large-scale Automated Serologic Testing for COVID-19". The purpose of this study is to determine how peoples' bodies respond to exposure to COVID-19. Employees of Beaumont Health in Michigan who are older than 18 years may be eligible to participate. Participants from other high-risk groups who are not Beaumont employees may also be recruited, as may fa...

What is the current status of trial NCT04349202?

This trial is currently completed. The enrollment target is 20,614 participants. The study started on 2020-04-10. Estimated completion is 2021-01-19.

What interventions are being tested in trial NCT04349202?

The interventions under investigation include: EUROIMMUN assay (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04349202?

This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.